Vascular Biogenics (NASDAQ:VBLT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Saturday.

According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “

VBLT has been the topic of a number of other reports. Chardan Capital raised their price target on shares of Vascular Biogenics from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, November 6th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Vascular Biogenics in a research report on Tuesday, November 7th. Finally, ValuEngine upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $15.67.

Vascular Biogenics (NASDAQ:VBLT) traded down $0.30 during trading on Friday, hitting $7.95. 243,026 shares of the stock were exchanged, compared to its average volume of 202,323. Vascular Biogenics has a one year low of $3.90 and a one year high of $9.05. The company has a market cap of $245.23, a P/E ratio of -10.06 and a beta of -3.00.

An institutional investor recently bought a new position in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Vascular Biogenics Ltd. (NASDAQ:VBLT) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned 0.08% of Vascular Biogenics as of its most recent SEC filing. Institutional investors and hedge funds own 6.59% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Vascular Biogenics (VBLT) Lifted to Hold at Zacks Investment Research” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/06/vascular-biogenics-vblt-lifted-to-hold-at-zacks-investment-research.html.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.